Zobrazeno 1 - 10
of 152
pro vyhledávání: '"David O. Toft"'
Autor:
Charles Erlichman, David O. Toft, Robert B. Jenkins, Karla V. Ballman, Bruce W. Morlan, Bridget Stensgard, Cynthia J. TenEyck, Andrea K. McCollum
Supplementary Figure Legends 1-2 from P-Glycoprotein–Mediated Resistance to Hsp90-Directed Therapy Is Eclipsed by the Heat Shock Response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1537ba5f2e021014f1b122eb7aefb138
https://doi.org/10.1158/0008-5472.22373784
https://doi.org/10.1158/0008-5472.22373784
Autor:
Charles Erlichman, David O. Toft, Robert B. Jenkins, Karla V. Ballman, Bruce W. Morlan, Bridget Stensgard, Cynthia J. TenEyck, Andrea K. McCollum
Despite studies that show the antitumor activity of Hsp90 inhibitors, such as geldanamycin (GA) and its derivative 17-allylamino-demethoxygeldanamycin (17-AAG), recent reports indicate that these inhibitors lack significant single-agent clinical acti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9248c0ced9e619ed5466f7d593c91034
https://doi.org/10.1158/0008-5472.c.6497208
https://doi.org/10.1158/0008-5472.c.6497208
Autor:
Charles Erlichman, David O. Toft, Robert B. Jenkins, Karla V. Ballman, Bruce W. Morlan, Bridget Stensgard, Cynthia J. TenEyck, Andrea K. McCollum
Supplementary Figure 2 from P-Glycoprotein–Mediated Resistance to Hsp90-Directed Therapy Is Eclipsed by the Heat Shock Response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ce4d0ccf34c929583d452537bdded69
https://doi.org/10.1158/0008-5472.22373787.v1
https://doi.org/10.1158/0008-5472.22373787.v1
Autor:
Charles Erlichman, David O. Toft, Robert B. Jenkins, Karla V. Ballman, Bruce W. Morlan, Bridget Stensgard, Cynthia J. TenEyck, Andrea K. McCollum
Supplementary Figure 1 from P-Glycoprotein–Mediated Resistance to Hsp90-Directed Therapy Is Eclipsed by the Heat Shock Response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cb9a745c1a9f33eabf5d7cdeb165929
https://doi.org/10.1158/0008-5472.22373790
https://doi.org/10.1158/0008-5472.22373790
Autor:
David O. Toft, William P. Sullivan
Publikováno v:
Receptor Phosphorylation ISBN: 9781351076241
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bd2abd031f670f79d11f408bb8364070
https://doi.org/10.1201/9781351076241-11
https://doi.org/10.1201/9781351076241-11
Autor:
Michael E. Menefee, Daniel Satele, R. Qin, David O. Toft, Matthew M. Ames, Erin L. Schenk, Donald W. Northfelt, Andrea E. Wahner Hendrickson, Charles Erlichman
Publikováno v:
Investigational New Drugs. 31:1251-1256
Purpose To determine the maximum tolerated dose (MTD) and characterize the dose-limiting toxicities (DLT) of tanespimycin when given in combination with bortezomib. Experimental design Phase I dose-escalating trial using a standard cohort “3+3” d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd2b008319fc7b09ed20fa1d01f6799a
https://doi.org/10.1007/s10637-013-9946-7
https://doi.org/10.1007/s10637-013-9946-7
Autor:
Charles Erlichman, Karla V. Ballman, Cynthia J. TenEyck, Bruce W. Morlan, Bridget Stensgard, Andrea K. McCollum, Robert B. Jenkins, David O. Toft
Publikováno v:
Cancer Research. 68:7419-7427
Despite studies that show the antitumor activity of Hsp90 inhibitors, such as geldanamycin (GA) and its derivative 17-allylamino-demethoxygeldanamycin (17-AAG), recent reports indicate that these inhibitors lack significant single-agent clinical acti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2097d1214d2975bfa1d84ac0341a5a9
https://doi.org/10.1158/0008-5472.can-07-5175
https://doi.org/10.1158/0008-5472.can-07-5175
Autor:
Dongxia Wang, Len Neckers, Bradley T. Scroggins, Shinji Tsutsumi, Robert J. Cotter, Sara J. Felts, David O. Toft, Kenneth Robzyk, Kristin Beebe, Larry M. Karnitz, Neal Rosen, Monica G. Marcu
Publikováno v:
Molecular Cell. 25(1):151-159
Heat shock protein 90 (Hsp90) chaperones a key subset of signaling proteins and is necessary for malignant transformation. Hsp90 is subject to an array of post-translational modifications which affect its function, including acetylation. Histone deac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e1865e6ce8d2b92838b784495cf8b18
Publikováno v:
Cancer Research. 66:10967-10975
17-Allylamino-demethoxygeldanamycin (17-AAG), currently in phase I and II clinical trials as an anticancer agent, binds to the ATP pocket of heat shock protein (Hsp90). This binding induces a cellular stress response that up-regulates many proteins i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f33823aa87f20dcad903eb925f6e6d1a
https://doi.org/10.1158/0008-5472.can-06-1629
https://doi.org/10.1158/0008-5472.can-06-1629
Autor:
Alex A. Adjei, Sumithra J. Mandrekar, Grzegorz S. Nowakowski, Matthew M. Ames, Andrea K. McCollum, Stephanie L. Safgren, Charles Erlichman, David O. Toft, Joel M. Reid
Publikováno v:
Clinical Cancer Research. 12:6087-6093
Purpose: To determine the maximum tolerated dose (MTD), dose-limiting toxicity, and pharmacokinetics of 17-allylamino-demethoxy-geldanamycin (17-AAG) administered on days 1, 4, 8, and 11 every 21 days and to examine the effect of 17-AAG on the levels
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c31681c2364a3af47a6e09cf1dbc7c4c
https://doi.org/10.1158/1078-0432.ccr-06-1015
https://doi.org/10.1158/1078-0432.ccr-06-1015